Market Cap 600.20M
Revenue (ttm) 0.00
Net Income (ttm) -61.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.18
Volume 43,726
Avg Vol 293,644
Day's Range N/A - N/A
Shares Out 31.07M
Stochastic %K 77%
Beta 2.78
Analysts Strong Sell
Price Target $31.25

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 200 0412
Address:
650 Castro Street, Suite 450, Mountain View, United States
optionravi
optionravi Feb. 20 at 4:10 PM
$ANRO Alto Neuroscience develops precision psychiatry treatments. Valuation is driven by clinical data and biomarker validation. Early-stage risk remains high.
0 · Reply
MOOSEN
MOOSEN Feb. 18 at 12:03 AM
$ANRO SO WHAT DA FUH?
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Feb. 17 at 9:47 PM
$ANRO $ALT $PYPD When I first bought into ANRO, I thought I was being reckless. I worried that I had bought too much... Now.... I realize I didn't buy enough. Won't make the same mistake with POLYPID.
0 · Reply
Ccperk
Ccperk Feb. 17 at 9:37 PM
$ANRO love seeing all the 13/Gs pouring in. It appears confidence is through the roof.
0 · Reply
KingVictorX
KingVictorX Feb. 17 at 6:47 PM
0 · Reply
erevnon
erevnon Feb. 17 at 11:17 AM
BTIG maintains Alto Neuroscience $ANRO at Buy and raises the price target from $27 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Ccperk
Ccperk Feb. 14 at 9:26 PM
$ANRO 10 day period, 7 day washout period, then another 10 day drug period. That estimated timeline tells me results may be ready mid March. I speculate investors will start loading up massively between now and then. Not financial advice, GL.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 3:23 PM
$ANRO RSI: 34.86, MACD: -0.2748 Vol: 0.80, MA20: 16.37, MA50: 16.14 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 1:22 PM
$ANRO Brilliant piece that captures ANRO's situation perfectly. So if you want to update your understanding of ANRO or get to know ANRO better, this is essential reading. https://everyticker.com/quote/ANRO/analysis/alto-neuroscience-unlocking-precision-psychiatry-with-biomarkers-and-a-deep-pipeline-nyse-anro
0 · Reply
S_Franconi
S_Franconi Feb. 3 at 3:00 PM
$ANRO Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment https://investors.altoneuroscience.com/news/default.aspx
1 · Reply
Latest News on ANRO
Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026

Nov 28, 2025, 12:38 PM EST - 3 months ago

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026


optionravi
optionravi Feb. 20 at 4:10 PM
$ANRO Alto Neuroscience develops precision psychiatry treatments. Valuation is driven by clinical data and biomarker validation. Early-stage risk remains high.
0 · Reply
MOOSEN
MOOSEN Feb. 18 at 12:03 AM
$ANRO SO WHAT DA FUH?
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Feb. 17 at 9:47 PM
$ANRO $ALT $PYPD When I first bought into ANRO, I thought I was being reckless. I worried that I had bought too much... Now.... I realize I didn't buy enough. Won't make the same mistake with POLYPID.
0 · Reply
Ccperk
Ccperk Feb. 17 at 9:37 PM
$ANRO love seeing all the 13/Gs pouring in. It appears confidence is through the roof.
0 · Reply
KingVictorX
KingVictorX Feb. 17 at 6:47 PM
0 · Reply
erevnon
erevnon Feb. 17 at 11:17 AM
BTIG maintains Alto Neuroscience $ANRO at Buy and raises the price target from $27 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Ccperk
Ccperk Feb. 14 at 9:26 PM
$ANRO 10 day period, 7 day washout period, then another 10 day drug period. That estimated timeline tells me results may be ready mid March. I speculate investors will start loading up massively between now and then. Not financial advice, GL.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 3:23 PM
$ANRO RSI: 34.86, MACD: -0.2748 Vol: 0.80, MA20: 16.37, MA50: 16.14 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 1:22 PM
$ANRO Brilliant piece that captures ANRO's situation perfectly. So if you want to update your understanding of ANRO or get to know ANRO better, this is essential reading. https://everyticker.com/quote/ANRO/analysis/alto-neuroscience-unlocking-precision-psychiatry-with-biomarkers-and-a-deep-pipeline-nyse-anro
0 · Reply
S_Franconi
S_Franconi Feb. 3 at 3:00 PM
$ANRO Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment https://investors.altoneuroscience.com/news/default.aspx
1 · Reply
Ccperk
Ccperk Jan. 22 at 3:23 PM
$ANRO HC reiterated their $50 buy rating yesterday….
0 · Reply
S_Franconi
S_Franconi Jan. 15 at 3:53 AM
$ANRO Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression https://investors.altoneuroscience.com/news/news-details/2026/Alto-Neuroscience-Strengthens-Intellectual-Property-Portfolio-with-Issuance-of-New-Method-of-Treatment-Patent-for-ALTO-207-in-Depression/default.aspx
0 · Reply
prismmarketview
prismmarketview Jan. 14 at 3:22 PM
Alto Neuroscience (NYSE: $ANRO) has secured a new U.S. patent for using its ALTO‑207 combo of pramipexole and ondansetron to treat depression, extending IP protection into the mid‑2040s. https://prismmarketview.com/alto-neuroscience-adds-new-alto-207-patent-in-depression/
0 · Reply
StreetwiseReports
StreetwiseReports Jan. 7 at 8:20 PM
How Do Analysts Rate This Biopharma Targeting Psychiatric Disorders https://ow.ly/oOAy50XT9pq Alto Neuroscience Inc. ($ANRO:NYSE) is developing drug candidates for psychiatric and neurological disorders, utilizing a precision approach rather than a one-size-fits-all method. Read to find out how analysts rate this company.
0 · Reply
signaljumper
signaljumper Jan. 7 at 6:52 AM
$TCRX new stockreport is out last performance from reports $ANRO up over 200% $GLSI 150%, $MLTX over 60% checkout the new report: https://www.patreon.com/posts/tcrx-tscan-inc-147617133?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link
1 · Reply
Ccperk
Ccperk Jan. 6 at 4:00 PM
$ANRO I’m not selling yet….top line data is due Q1 2026 for their fast tracked product Alto-101, using their innovative biomarker strategy. This will be a HUGE milestone imho. I think there is some hedging going on from that purchase agreement last Oct.
1 · Reply
rick_b
rick_b Jan. 6 at 3:39 PM
$ANRO Somebody knows something. 10:33am 1/6/26
0 · Reply
Tstockwizard
Tstockwizard Jan. 3 at 6:04 PM
0 · Reply
rpc630
rpc630 Dec. 30 at 3:32 PM
$SLS $ANRO $OTLK $TEAD AGREED 👍 🤝 👌
0 · Reply
Ccperk
Ccperk Dec. 26 at 5:55 PM
$ANRO looks like a bunch of bot trading taking place right now. Whoopee 🙄
0 · Reply
ALRAE
ALRAE Dec. 24 at 1:57 AM
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 22 at 7:09 PM
$ANRO hang on longs *
0 · Reply